f Vutrisiran for Transthyretin Amyloidosis Cardiomyopathy

References

1. Ream S. Ma J. Rodriguez T. Ethnic/racial differences in risk factors and clinical outcomes among patients with amyloidosis. Am. J. Med. Sci. 2023 365 3 232 241 10.1016/j.amjms.2022.12.009 36543303
   [Google Scholar]
2. Isath A. Correa A. Siroky G.P. Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16‐year nationwide study from 1999 to 2014. J. Arrhythm. 2020 36 4 727 734 10.1002/joa3.12376 32782646
   [Google Scholar]
3. Ang S.P. Chia J.E. Deshmukh A.J. Efficacy and clinical outcomes of catheter ablation for atrial arrhythmia in cardiac amyloidosis. Heart Rhythm 2025 22 3 865 867 10.1016/j.hrthm.2024.08.025 39151713
   [Google Scholar]
4. Benson M.D. Buxbaum J.N. Eisenberg D.S. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018 25 4 215 219 10.1080/13506129.2018.1549825 30614283
   [Google Scholar]
5. Castaño A. Narotsky D.L. Hamid N. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur. Heart J. 2017 38 38 2879 2887 10.1093/eurheartj/ehx350 29019612
   [Google Scholar]
6. González-López E. Gallego-Delgado M. Guzzo-Merello G. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J. 2015 36 38 2585 2594 10.1093/eurheartj/ehv338 26224076
   [Google Scholar]
7. Gillmore J.D. Judge D.P. Cappelli F. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 2024 390 2 132 142 10.1056/NEJMoa2305434 38197816
   [Google Scholar]
8. Aimo A. Castiglione V. Rapezzi C. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol. 2022 19 10 655 667 10.1038/s41569‑022‑00683‑z 35322226
   [Google Scholar]
9. Ang S.P. Chia J.E. Mukherjee D. Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy. Heart Fail. Rev. 2025 Epub ahead of print10.1007/s10741‑025‑10502‑5 40056371
   [Google Scholar]
10. Benson M.D. Waddington-Cruz M. Berk J.L. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med. 2018 379 1 22 31 10.1056/NEJMoa1716793 29972757
    [Google Scholar]
11. Maurer M.S. Kale P. Fontana M. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N. Engl. J. Med. 2023 389 17 1553 1565 10.1056/NEJMoa2300757 37888916
    [Google Scholar]
12. Hellenbart E.L. Ipema H.J. Rodriguez-Ziccardi M.C. Krishna H. DiDomenico R.J. Disease‐modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. Pharmacotherapy 2025 45 2 124 144 10.1002/phar.4639 39714070
    [Google Scholar]
13. Sekijima Y. Sousa L. Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis. Amyloid 2024 2024 1 12 10.1080/13506129.2024.2435573 39627935
    [Google Scholar]
14. Adams D. Tournev I.L. Taylor M.S. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 2023 30 1 18 26 10.1080/13506129.2022.2091985 35875890
    [Google Scholar]
15. Fontana M. Berk J.L. Gillmore J.D. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N. Engl. J. Med. 2025 392 1 33 44 10.1056/NEJMoa2409134 39213194
    [Google Scholar]
16. Maurer M.S. Schwartz J.H. Gundapaneni B. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 2018 379 11 1007 1016 10.1056/NEJMoa1805689 30145929
    [Google Scholar]
17. Merlini G. Vutrisiran for ATTR amyloidosis with cardiomyopathy. N. Engl. J. Med. 2025 392 1 83 84 10.1056/NEJMe2411602 39752304
    [Google Scholar]
18. Masoudi F.A. Vutrisiran for cardiomyopathy associated with transthyretin amyloidosis. Available from 2024 [https://www.jwatch.org/na57895/2024/09/04/vutrisiran-cardiomyopathy-associated-with-transthyretin
    [Google Scholar]
19. Vutrisiran (Amvuttra) CADTH Reimbursement Recommendation: Indication: For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis. Ottawa, ON Canadian Agency for Drugs and Technologies in Health 2024
    [Google Scholar]